Tamar Thompson
Director/Board Member bij AVIDITY BIOSCIENCES, INC.
Vermogen: - $ op 31-03-2024
Profiel
Tamar Thompson is currently serving as the Chairman of the Alexion Charitable Foundation.
Additionally, Ms. Thompson holds the position of Independent Director at Catalyst Pharmaceuticals, Inc. since 2023, Independent Director at Avidity Biosciences, Inc. since 2021, and Vice President of US Government Affairs & Policy at Alexion Pharmaceuticals, Inc. since 2019.
Ms. Thompson previously worked at Bristol Myers Squibb Co. as the Head of Federal Executive Branch Strategy from 2015 to 2019.
Ms. Thompson obtained a graduate degree from Trident University International.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
-.--% | 15-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Tamar Thompson
| Bedrijven | Functie | Begin |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Director/Board Member | 11-01-2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-11-2019 |
| CATALYST PHARMACEUTICALS, INC. | Director/Board Member | 25-05-2023 |
| Alexion Charitable Foundation | Chairman | - |
Eerdere bekende functies van Tamar Thompson
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-11-2019 |
Opleiding van Tamar Thompson
| Trident University International | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Alexion Charitable Foundation |
